18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer

被引:18
|
作者
Salem, Kelley [1 ]
Kumar, Manoj [1 ]
Powers, Ginny L. [1 ,5 ]
Jeffery, Justin J. [2 ]
Yan, Yongjun [1 ,3 ]
Mahajan, Aparna M. [4 ]
Fowler, Amy M. [1 ,2 ,3 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, 600 Highland Ave, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, 600 Highland Ave, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, 600 Highland Ave, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, 600 Highland Ave, Madison, WI 53792 USA
[5] Kendrick Labs, Madison, WI USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; PROTEASOME-MEDIATED PROTEOLYSIS; SMALL-ANIMAL PET; IN-VIVO; TARGET TISSUES; ESR1; MUTATIONS; F-18-FLUOROESTRADIOL; THERAPY; RESPONSIVENESS; FEASIBILITY;
D O I
10.1148/radiol.2017162956
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the binding specificity of F-18-16 alpha-17 beta-fluoroestradiol (FES) in estrogen receptor (ER) alpha-positive breast cancer cells and tumor xenografts. Materials and Methods: Protocols were approved by the office of biologic safety and institutional animal care and use committee. By using ER-negative MDA-MB-231 breast cancer cells, clonal lines were created that expressed either wild-type (WT; 231 WT ER) or G521R mutant ER alpha (231 G521R ER), which is defective in estradiol binding. ERa protein levels, subcellular localization, and transcriptional function were confirmed. FES binding was measured by using an in vitro cell uptake assay. In vivo FES uptake was measured in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imaging of 24 mice (17 WT ER tumors, nine mutant G521R ER tumors, eight MDA-MB-231 tumors, and four MCF-7 ER-positive tumors). Statistical significance was determined by using Mann-Whitney (Wilcoxon rank sum) test. Results: ERa transcriptional function was abolished in the mutated 231 G521R ER cells despite appropriate receptor protein expression and nuclear localization. In vitro FES binding in the 231 G521R ER cells was reduced to that observed in the parental cells. Similarly, there was no significant FES uptake in the 231 G521R ER xenografts (percent injected dose [ ID] per gram, 0.49 +/- 0.042), which was similar to the negative control MDA-MB-231 xenografts (percent ID per gram, 0.42 +/- 0.051; P =.20) and nonspecific muscle uptake (percent ID per gram, 0.41 +/- 0.0095; P =.06). Conclusion: This study showed that FES retention in ER-positive breast cancer is strictly dependent on an intact receptor ligand-binding pocket and that FES binds to ERa with high specificity. These results support the utility of FES imaging for assessing tumor heterogeneity by localizing immunohistochemically ER-positive metastases that lack receptor-binding functionality. (C) RSNA, 2017
引用
收藏
页码:868 / 876
页数:9
相关论文
共 50 条
  • [1] 18F-Fluoroestradiol PET/CT for Staging Low-Grade Estrogen Receptor-Positive Breast Cancer
    Fowler, Amy M.
    RADIOLOGY, 2025, 314 (03)
  • [2] 16-ALPHA-[F-18]-FLUOROESTRADIOL - A POSITRON-EMITTING IMAGING AGENT FOR ESTROGEN RECEPTOR-POSITIVE BREAST-TUMORS
    KATZENELLENBOGEN, JA
    BRODACK, JW
    MATHIAS, CJ
    KILBOURN, MR
    MINTUN, MA
    WELCH, MJ
    ANTICANCER RESEARCH, 1986, 6 (03) : 363 - 364
  • [3] Factors influencing the uptake of 18F-fluoroestradiol in patients with estrogen receptor positive breast cancer
    Peterson, Lanell M.
    Kurland, Brenda F.
    Link, Jeanne M.
    Schubert, Erin K.
    Stekhova, Svetlana
    Linden, Hannah M.
    Mankoff, David A.
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (07) : 969 - 978
  • [4] 18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer
    Yamane, Tomohiko
    Ueda, Shigeto
    Seto, Akira
    Kuji, Ichiei
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (05) : 379 - 380
  • [5] Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer
    Sun Young Chae
    Hye Joo Son
    Dong Yun Lee
    Eonwoo Shin
    Jungsu S. Oh
    Seung Yeon Seo
    Sora Baek
    Ji Young Kim
    Sae Jung Na
    Dae Hyuk Moon
    EJNMMI Research, 10
  • [6] Predictive value of (16 alpha[18-F]-fluoroestradiol) FES-PET in recurrent estrogen receptor positive (ER plus ) breast cancer
    Roy, Felix-Nicolas
    Croteau, Etienne
    Ouellet, Rene
    Bujold, Rachel
    Forget, Andre
    Dufresne, Jean
    van Lier, Johannes
    Benard, Francois
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [7] Comparison of diagnostic sensitivity of [18F]fluoroestradiol and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer
    Chae, Sun Young
    Son, Hye Joo
    Lee, Dong Yun
    Shin, Eonwoo
    Oh, Jungsu S.
    Seo, Seung Yeon
    Baek, Sora
    Kim, Ji Young
    Na, Sae Jung
    Moon, Dae Hyuk
    EJNMMI RESEARCH, 2020, 10 (01)
  • [8] Comparison of diagnostic accuracy of 18F-fluoroestradiol and 18F-fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer
    Young, Chae Sun
    Son, Hye Joo
    Lee, Dong Yun
    Oh, Jungsu
    Seo, Seung Yeon
    Baek, Sora
    Kim, Ji Young
    Na, Sae Jung
    Moon, Dae Hyuk
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [9] Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol
    Peterson, Lanell M.
    Mankoff, David A.
    Lawton, Thomas
    Yagle, Kevin
    Schubert, Erin K.
    Stekhova, Svetlana
    Gown, Allen
    Link, Jeanne M.
    Tewson, Timothy
    Krohn, Kenneth A.
    JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (03) : 367 - 374
  • [10] [18F]-fluoroestradiol (FES) Brain PET in the Evaluation of Patients with Estrogen Receptor Positive Breast Cancer Brain Metastases
    Sharbatdaran, Arman
    Osborne, Joseph
    Agee, Matthew
    Magge, Rajiv
    Jonathan, Knisely
    Schwartz, Theodore
    Pannullo, Susan
    Brandmaier, Andrew
    Andreopoulou, Eleni
    Ramakrishna, Rohan
    Ivanidze, Jana
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65